Subscribe
blackboard1965-shutterstock-com-pills-
blackboard1965 / Shutterstock.com
30 March 2016Americas

Shire wins Lialda patent trial against Watson

Biopharmaceutical company Shire has had a patent for Lialda (mesalamine) upheld in its trial against Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.

More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.

More features

Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application
Outlook for 2025: how Trump and the USPTO will affect life sciences IP
Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows